Key result
Ataluren plus standard of care delayed the median age at loss of ambulation by 4 years compared with standard of care alone in patients with nonsense mutation Duchenne muscular dystrophy.
Why the study?
Real-world characteristics, safety, and effectiveness of ataluren plus standard of care compared with standard of care alone in individuals with nonsense mutation Duchenne muscular dystrophy required evaluation.
Does ataluren plus standard of care delay disease progression milestones compared to standard of care alone in patients with nonsense mutation Duchenne muscular dystrophy?
Observational (n=747)
Yes
Does ataluren plus standard of care delay disease progression milestones compared to standard of care alone in patients with nonsense mutation Duchenne muscular dystrophy?
Real-world treatment with ataluren plus standard of care significantly delays loss of ambulation and respiratory decline in patients with nonsense mutation Duchenne muscular dystrophy compared to standard of care alone.
Answers are grounded in this paper and cite their sources.
May support ataluren consideration in nonsense mutation DMD; leaves open randomized confirmation before practice change.
OBJECTIVE: Strategic Targeting of Registries and International Database of Excellence (STRIDE) is an ongoing, international, multicenter registry of real-world ataluren use in individuals with nonsense mutation Duchenne muscular dystrophy (nmDMD) in clinical practice. This updated interim report (data cut-off: January 31, 2022), describes STRIDE patient characteristics and ataluren safety data, as well as the effectiveness of ataluren plus standard of care (SoC) in STRIDE versus SoC alone in the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS). METHODS: Patients are followed up from enrollment for at least 5 years or until study withdrawal. Propensity score matching was performed to identify STRIDE and CINRG DNHS patients who were comparable in established predictors of disease progression. RESULTS: As of January 31, 2022, 307 patients were enrolled from 14 countries. Mean (standard deviation [SD]) ages at first symptoms and at genetic diagnosis were 2.9 (1.7) years and 4.5 (3.7) years, respectively. Mean (SD) duration of ataluren exposure was 1671 (56.8) days. Ataluren had a favorable safety profile; most treatment-emergent adverse events were mild or moderate and unrelated to ataluren. Kaplan-Meier analyses demonstrated that ataluren plus SoC significantly delayed age at loss of ambulation by 4 years (p < 0.0001) and age at decline to %-predicted forced vital capacity of < 60% and < 50% by 1.8 years (p = 0.0021) and 2.3 years (p = 0.0207), respectively, compared with SoC alone. CONCLUSION: Long-term, real-world treatment with ataluren plus SoC delays several disease progression milestones in individuals with nmDMD. NCT02369731; registration date: February 24, 2015.
No takes yet. Share an insight, caveat, or question.
Mercuri et al. (2023) conducted an observational in Nonsense mutation Duchenne muscular dystrophy (nmDMD) (n=747). Ataluren plus standard of care vs. Standard of care alone was evaluated on Age at loss of ambulation (HR 0.375, 95% CI 0.277-0.508, p=<0.0001). Ataluren plus standard of care delayed the median age at loss of ambulation by 4 years compared with standard of care alone in patients with nonsense mutation Duchenne muscular dystrophy.
Synapse has enriched 10 related papers. Consider them for comparative context: